AngioDynamics ANGO Business Segments
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Med Device | $18.19M-5.6% | $21.5M+8.6% | $19.94M+4.8% | $21.1M+7.0% | $19.27M-3.7% | |
| Med Tech | $23.29M+18.9% | $23.29M+15.8% | $21.92M+23.9% | $21.12M+12.3% | $19.59M+23.5% | |
| Cost of sales (exclusive of intangible amortization) by Business | ||||||
| Med Device | $22.95M+7.3% | $22.28M+3.7% | $20.52M+0.1% | $23.27M-15.4% | $21.39M-22.2% | |
| Med Tech | $13.99M+19.0% | $12.37M+8.1% | $13.34M+29.9% | $14.67M+49.7% | $11.75M+19.9% | |
| Gross Margin % by Business | ||||||
| Med Device | 44.2%-3.2pp | 49.1%+1.2pp | 49.3%+1.2pp | —— | 47.4%+6.9pp | |
| Med Tech | 62.5%0.0pp | 65.3%+1.6pp | 62.2%-1.1pp | —— | 62.5%+1.1pp | |
| Net Sales by Product | ||||||
| Med Device | $41.14M+1.2% | $43.78M+6.0% | $40.45M+2.3% | $44.37M+6.5% | $40.66M-17.6% | |
| Med Tech | $37.28M+19.0% | $35.65M+13.0% | $35.26M+26.1% | $35.79M+22.0% | $31.34M+21.3% | |
| Net Sales by Geography | ||||||
| International | $11.15M+4.5% | $11.84M+16.4% | $9.26M+15.5% | $12.67M+23.8% | $10.66M-16.9% | |
| United States | $67.28M+9.7% | $67.59M+7.8% | $66.46M+11.7% | $67.48M+11.1% | $61.34M-1.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AngioDynamics break its business down?
- AngioDynamics (ANGO) reports gross profit by business across 2 parts — Med Device and Med Tech. Each is extracted from the segment footnotes and tracked over time.
- Where does AngioDynamics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AngioDynamics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
